– Advertisement – Reigning world champions South Africa intend to remain a part of the Rugby Championship – Advertisement – “The southern hemisphere rugby powers have recognised the need for change in these difficult times and have committed to an international rugby future through to 2030,” SANZAAR said in a statement.SANZAAR chief executive Andy Marinos added: “The re-commitment by the four unions to the long-term future of the international game is an important start as we embark in a new direction. South Africa withdrew from this year’s Rugby Championship over player welfare concerns; the country’s Super Rugby franchises could joined an expanded PRO16 Last Updated: 04/11/20 7:44am
Topics : “Our confidence has increased. We have work to do like everybody on manufacturing in large volumes. But we will have one, maybe two vaccines next year,” Hudson said.Translate Bio said on Tuesday the mRNA vaccine had induced an immune response in non-human studies, with trials in humans expected to start in November.Sanofi has secured deals for the vaccine-plus-adjuvant with the United States and Britain, and is in advanced talks with the European Union to supply it with up to 300 million doses.But the EU is offering only partial protection to vaccine makers against legal risks from side-effects of their potential shots, European officials said earlier this week, in a move that is hampering deals and contrasts with U.S. policy.”I think with the level of protection, we have reached an ‘agreed level’. And I think that has allowed us to go forward and sign. But I am aware there are different positions on how strong that is,” Hudson said.With vaccines being developed at record speed during the pandemic, there is potentially a greater risk they may have unexpected consequences or may not be effective.The financial coverage of these liabilities is a key feature of drugmakers’ talks with governments keen to secure vaccine shots in advance.There is so far no approved coronavirus vaccine, except one authorized in Russia before large-scale trials. The other, being developed with U.S. company Translate Bio , relies on a different technology known as mRNA.”The early data is saying that we’re on the right track and that we have a vaccine,” Paul Hudson said in an interview on Friday, referring to the vaccine being developed with GSK.That vaccine is set to start clinical trials next month.Around 30 experimental coronavirus shots are already in human trials. But Hudson said in June the probability of Sanofi obtaining a vaccine with an efficacy of more than 70% was higher than for rivals, in part due to its experience in vaccines. Sanofi’s confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the COVID-19 pandemic, which has claimed more than 831,000 lives and sparked economic chaos.One candidate, to be manufactured on the back of an existing platform that develops vaccines to treat flu, will use an adjuvant made by Britain’s GlaxoSmithKline (GSK) to boost its efficacy.
Race relations are a critical fault line in South Africa, with over 500 racism-related cases reported to the South African Human Rights Commission in the past year alone.The United Nations has recently warned that racism, intolerance and discrimination are increasing in many parts of the world. There has been a resurgence of overt racism in South Africa.The Nelson Mandela and Ahmed Kathrada Foundations – both with long histories of facilitating critical dialogue on issues of race relations – have partnered with other civil society organisations to respond to and better understand race relations in the country. Both organizations want to ensure that anti racism strategies are mainstreamed across all sectors of the country. The anti racism network’s ultimate vision is of a South Africa free of racism.
NBA free agency rumors: At least 5 teams expected to pursue Tobias Harris The Pacers finished 2018-19 with a 48-34 record and were swept by the Celtics in the first round of the playoffs.Guards Darren Collison and Cory Joseph are both set to be free agents this summer while the team has reportedly made Ricky Rubio a “top target.” Indiana, however, says it isn’t shopping Holiday and stopped taking calls about him following the trade deadline, the report says.The Pacers selected Holiday out of UCLA with the 23rd pick in the 2018 draft. He averaged 5.9 points and 1.7 assists in 50 games as a rookie. Related News The Pacers could have multiple options if they decide to deal Aaron Holiday.The Suns, Timberwolves and Bulls are all interested in dealing for the 22-year-old guard, according to a report from the Indianapolis Star, which cites unidentified league sources. “You don’t know when you’re going to get called or what’s going to happen,” Holiday told The Athletic last month. “You just get thrown out there. So probably staying ready. I think I did a good job with that. It was tough at times because you don’t know what’s happening out there.”Holiday was in-and-out of Indiana’s rotation last season. He shot 40.1% from the field and 33.9% from 3-point range in about 12.9 minutes per appearance.“I feel he should be a rotational player next season and a guy that can play the one and the two,” Indiana coach Nate McMillan said in May. “I’m very comfortable with him. He’s a young kid that has a great deal of confidence in himself and I think he could help us.” NBA free agency rumors: Pacers have made Ricky Rubio a ‘top target’